| 欧剑锋 王蕾 潘耀柱 张姝婷 白海.嵌合抗原受体修饰T 细胞免疫治疗肿瘤的研究进展[J].,2016,16(2):373-376 |
| 嵌合抗原受体修饰T 细胞免疫治疗肿瘤的研究进展 |
| Advances in Cancer Immunotherapy Adopting Chimeric AntigenReceptor-modified T Lymphocytes |
| |
| DOI： |
| 中文关键词: 嵌合抗原受体 T细胞 免疫治疗 肿瘤 |
| 英文关键词: Chimeric antigen receptor T lymphocytes Immunotherapy Tumor |
| 基金项目:国家自然科学基金项目（81372132） |
|
| 摘要点击次数: 843 |
| 全文下载次数: 0 |
| 中文摘要: |
| 以嵌合抗原受体修饰T 细胞（chimeric antigen receptor modified -T lymphocytes, CAR-T）为基础的过继细胞免疫治疗近年来
成为治疗恶性肿瘤的一种新模式。CAR-T细胞赋予T细胞靶向杀伤活性，并可克服肿瘤免疫抑制和打破宿主免疫耐受。尽管目前
CAR-T 的临床应用还存在诸如脱靶效应、细胞因子风暴、插入突变和移植物抗宿主病样损伤等许多问题，但我们相信随着对
CAR-T细胞的深入研究及推广应用将会大幅度提高肿瘤的临床治疗效果。本文就CAR-T细胞应用于肿瘤免疫治疗的前生、今世
和将来作一综述。 |
| 英文摘要: |
| Chimeric antigen receptor modified-T lymphocytes (CAR-T) based adoptive antitumor immunotherapy has became an
emerging therapeutic modality for malignant tumor in recent years. CAR-T cells give the targeted killing activity of T lymphocytes,
which they can resist the tumor immunosuppression and break the host immune tolerance. Although there still exist many problems for
CAR-T on the clinical application such as off-target effects, cytokine storm, insertion mutagenesis, graft versus host disease-like damage
and many other problems, but we believe that with the in-depth study of the CAR-T cells and application will greatly improve the
therapeutic effects of tumor. We summarized the past history, present status and future prospect of tumor immunotherapy adopting
CAR-T in this review. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
